What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The evidence from the ECHELON-1 trial demonstrates that brentuximab vedotin in combination with doxorubicin, dacarbazine, and vinblastine significantly improves progression-free survival and overall survival compared to ABVD, with hazard ratios of 0.677 and 0.617 respectively. This indicates a clear clinical advantage over the standard of care.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for brentuximab vedotin are within the acceptable range for Healthcare resources, with the ICER being below the middle of NICE’s threshold for cost-effectiveness. This indicates a strong economic value for the treatment.
Is there quality-of-life evidence payers weigh? — Quality of life
The trial included quality of life assessments, and while the results showed improvements, they were moderate and based on subgroup data. The committee acknowledged the impact of the treatment on quality of life, but the improvements were not overwhelmingly large.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Brentuximab vedotin has an acceptable safety profile, with manageable adverse events. Although there were more treatment-emergent adverse events compared to ABVD, the overall safety was considered acceptable with notable adverse events being manageable.
Was the drug compared against what payers expect? — Comparator Selection
The comparator used was a weighted average of ABVD treatment regimens, which reflects clinical practice. However, there was no direct head-to-head data comparing brentuximab combination with the PET-adapted ABVD, leading to some limitations in the evidence.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was broadly representative of the intended patient population, with a significant sample size of 1,334 participants. The committee noted that the population included relevant subgroups, enhancing generalizability.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Brentuximab vedotin can be integrated into existing treatment pathways with minor adjustments. The treatment aligns well with current clinical practices, requiring no significant changes to infrastructure.
Are the wider system costs understood? — Resource Use and Cost Implications
The resource implications of brentuximab vedotin are manageable, with the potential for cost savings due to its effectiveness. The committee concluded that the budget impact is justifiable given the treatment’s benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a robust Phase 3 RCT (ECHELON-1) with a large sample size and long-term follow-up, providing strong support for the treatment’s efficacy and safety. The committee found the evidence credible and reliable.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are some uncertainties regarding the generalizability of the trial population to the broader patient population, particularly concerning age distribution. However, the committee felt that these uncertainties were manageable.
